UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
 
SCHEDULE 13G*/
(Rule 13d-102)
 
 
  Zentalis Pharmaceuticals, Inc.
  (Name of Issuer)
 
  Common stock, par value $0.001 per share
(Title of Class of Securities)
 
 
 

98943L107

(CUSIP Number)
 
 
 

April 3, 2020

Date of Event Which Requires Filing of the Statement

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)

 

 

 

*/ The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP No.  98943L107 13G Page 2 of 14 Pages

 

 

1.

 

NAME OF REPORTING PERSON

 

 

Citadel Advisors LLC

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)       [_]

(b)   [_]

 

3.

 

SEC USE ONLY

 

 

4.

 

 

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

 

5.

 

SOLE VOTING POWER

0

 

6.

 

SHARED VOTING POWER

 

2,129,766 shares

 

 

7.

 

SOLE DISPOSITIVE POWER

0

 

8.

 

 

SHARED DISPOSITIVE POWER

See Row 6 above

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

See Row 6 above

 

10.

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

CERTAIN SHARES [_]

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

5.9%1

 

12.

 

 

TYPE OF REPORTING PERSON

IA; OO; HC

       

 

 

1The percentages reported in this Schedule 13G are based upon 35,878,524 shares of common stock outstanding after the exercise of the underwriters’ option (as set forth in the issuer’s prospectus filed with the Securities and Exchange Commission on April 6, 2020). Except as described in the preceding sentence, all share numbers for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on April 9, 2020.

 

 

 

 

CUSIP No.  98943L107 13G Page 3 of 14 Pages

 

 

1.

 

NAME OF REPORTING PERSON

 

 

Citadel Advisors Holdings LP

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)       [_]

(b)   [_]

 

3.

 

SEC USE ONLY

 

 

4.

 

 

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

 

5.

 

SOLE VOTING POWER

0

 

6.

 

SHARED VOTING POWER

 

2,129,766 shares

 

 

7.

 

SOLE DISPOSITIVE POWER

0

 

8.

 

 

SHARED DISPOSITIVE POWER

See Row 6 above

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

See Row 6 above

 

10.

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

CERTAIN SHARES [_]

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

5.9%

 

12.

 

 

TYPE OF REPORTING PERSON

PN; HC

       

 

 

 

 

CUSIP No.  98943L107 13G Page 4 of 14 Pages

 

 

1.

 

NAME OF REPORTING PERSON

 

 

Citadel GP LLC

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)       [_]

(b)   [_]

 

3.

 

SEC USE ONLY

 

 

4.

 

 

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

 

5.

 

SOLE VOTING POWER

0

 

6.

 

SHARED VOTING POWER

 

2,129,766 shares

 

 

7.

 

SOLE DISPOSITIVE POWER

0

 

8.

 

 

SHARED DISPOSITIVE POWER

See Row 6 above.

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

See Row 6 above.

 

10.

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

CERTAIN SHARES [_]

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

5.9%

 

12.

 

 

TYPE OF REPORTING PERSON

OO; HC

       

 

 

 

 

CUSIP No.  98943L107 13G Page 5 of 14 Pages

 

 

1.

 

NAME OF REPORTING PERSON

 

 

Citadel Securities LLC

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)       [_]

(b)   [_]

 

3.

 

SEC USE ONLY

 

 

4.

 

 

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

 

5.

 

SOLE VOTING POWER

0

 

6.

 

SHARED VOTING POWER

 

198 shares

 

 

7.

 

SOLE DISPOSITIVE POWER

0

 

8.

 

 

SHARED DISPOSITIVE POWER

See Row 6 above.

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

See Row 6 above.

 

10.

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

CERTAIN SHARES [_]

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

Less than 0.1%

 

12.

 

 

TYPE OF REPORTING PERSON

BD, OO

       

 

 

 

 

CUSIP No.  98943L107 13G Page 6 of 14 Pages

 

 

1.

 

NAME OF REPORTING PERSON

 

 

CALC IV LP

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)       [_]

(b)   [_]

 

3.

 

SEC USE ONLY

 

 

4.

 

 

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

 

5.

 

SOLE VOTING POWER

0

 

6.

 

SHARED VOTING POWER

 

198 shares

 

 

7.

 

SOLE DISPOSITIVE POWER

0

 

8.

 

 

SHARED DISPOSITIVE POWER

See Row 6 above.

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

See Row 6 above.

 

10.

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

CERTAIN SHARES [_]

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

Less than 0.1%

 

12.

 

 

TYPE OF REPORTING PERSON

PN; HC

       

 

 

 

 

CUSIP No.  98943L107 13G Page 7 of 14 Pages

 

 

1.

 

NAME OF REPORTING PERSON

 

 

Citadel Securities GP LLC

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)       [_]

(b)   [_]

 

3.

 

SEC USE ONLY

 

 

4.

 

 

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

 

5.

 

SOLE VOTING POWER

0

 

6.

 

SHARED VOTING POWER

 

198 shares

 

 

7.

 

SOLE DISPOSITIVE POWER

0

 

8.

 

 

SHARED DISPOSITIVE POWER

See Row 6 above.

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

See Row 6 above.

 

10.

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

CERTAIN SHARES [_]

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

Less than 0.1%

 

12.

 

 

TYPE OF REPORTING PERSON

OO; HC

       

 

 

 

 

CUSIP No.  98943L107 13G Page 8 of 14 Pages

 

 

1.

 

NAME OF REPORTING PERSON

 

 

Kenneth Griffin

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)       [_]

(b)   [_]

 

3.

 

SEC USE ONLY

 

 

4.

 

 

CITIZENSHIP OR PLACE OF ORGANIZATION

U.S. Citizen

 

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

 

5.

 

SOLE VOTING POWER

0

 

6.

 

SHARED VOTING POWER

 

2,129,964 shares

 

 

7.

 

SOLE DISPOSITIVE POWER

0

 

8.

 

 

SHARED DISPOSITIVE POWER

See Row 6 above

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

See Row 6 above

 

10.

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

CERTAIN SHARES [_]

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

5.9%

 

12.

 

 

TYPE OF REPORTING PERSON

IN; HC

       

 

 

 

 

 

CUSIP No.  98943L107 13G Page 9 of 14 Pages

 

Item 1(a)Name of Issuer

Zentalis Pharmaceuticals, Inc.

 

Item 1(b)Address of Issuer’s Principal Executive Offices

 

530 Seventh Avenue, Suite 2201, New York, New York 10018

 

Item 2(a)Name of Person Filing
This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC (“Citadel Securities”), CALC IV LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the “Reporting Persons”) with respect to shares of common stock of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands limited company (“CM”), and Citadel Securities.

 

Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.

 

The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).

 

Item 2(b)Address of Principal Business Office
The address of the principal business office of each of the Reporting Persons is 131 S. Dearborn Street, 32nd Floor, Chicago, Illinois 60603.

 

Item 2(c)Citizenship
Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.

 

Item 2(d)Title of Class of Securities
Common stock, par value $0.001 per share

 

Item 2(e)CUSIP Number
98943L107

 

 

 

 

CUSIP No.  98943L107 13G Page 10 of 14 Pages

 

Item 3If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

 

(a)[__] Broker or dealer registered under Section 15 of the Exchange Act;

 

(b)[__] Bank as defined in Section 3(a)(6) of the Exchange Act;

 

(c)[__] Insurance company as defined in Section 3(a)(19) of the Exchange Act;

 

(d)[__] Investment company registered under Section 8 of the Investment Company Act;

 

(e)[__] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

 

(f)[__] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

 

(g)[__] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

 

(h)[__] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

 

(i)[__] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

 

(j)[__] A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

 

(k)[__] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

 

 

 

 

CUSIP No.  98943L107 13G Page 11 of 14 Pages

 

Item 4Ownership

 

A.Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC

 

(a)Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 2,129,766 shares of common stock.

 

(b)The number of shares each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes approximately 5.9% of the common stock outstanding.

 

(c)Number of shares as to which such person has:

 

(i)sole power to vote or to direct the vote: 0

 

(ii)shared power to vote or to direct the vote: 2,129,766

 

(iii)sole power to dispose or to direct the disposition of: 0

 

(iv)shared power to dispose or to direct the disposition of: 2,129,766

 

B.Citadel Securities LLC, CALC IV LP and Citadel Securities GP LLC

 

(a)Each of Citadel Securities, CALC IV LP and Citadel Securities GP LLC may be deemed to beneficially own 198 shares of common stock.

 

(b)The number of shares that each of Citadel Securities, CALC IV LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes less than 0.1% of the common stock outstanding.

 

(c)Number of shares as to which such person has:

 

(i)sole power to vote or to direct the vote: 0

 

(ii)shared power to vote or to direct the vote: 198

 

(iii)sole power to dispose or to direct the disposition of: 0

 

(iv)shared power to dispose or to direct the disposition of: 198

 

C.Kenneth Griffin

 

(a)Mr. Griffin may be deemed to beneficially own 2,129,964 shares of common stock.

 

(b)The number of shares that Mr. Griffin may be deemed to beneficially own constitutes approximately 5.9% of the common stock outstanding.

 

 

 

 

CUSIP No.  98943L107 13G Page 12 of 14 Pages

 

(c)Number of shares as to which such person has:

 

(i)sole power to vote or to direct the vote: 0

 

(ii)shared power to vote or to direct the vote: 2,129,964

 

(iii)sole power to dispose or to direct the disposition of: 0

 

(iv)shared power to dispose or to direct the disposition of: 2,129,964

 

 

 

 

 

CUSIP No.  98943L107 13G Page 13 of 14 Pages

 

Item 5Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [_].

 

Item 6Ownership of More than Five Percent on Behalf of Another Person

Not Applicable

 

Item 7Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company

See Item 2 above

 

Item 8Identification and Classification of Members of the Group

Not Applicable

 

Item 9Notice of Dissolution of Group

Not Applicable

 

Item 10Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

 

CUSIP No.  98943L107 13G Page 14 of 14 Pages

 

 

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

Dated this 9th day of April, 2020.

 

CITADEL SECURITIES LLC

 

By: /s/ Guy Miller

Guy Miller, Authorized Signatory

 

CITADEL ADVISORS LLC

 

By: /s/ Noah Goldberg

Noah Goldberg, Authorized Signatory

 

CALC IV LP

 

By: /s/ Guy Miller

Guy Miller, Authorized Signatory

 

CITADEL ADVISORS HOLDINGS LP

 

By: /s/ Noah Goldberg

Noah Goldberg, Authorized Signatory

 

CITADEL SECURITIES GP LLC

 

By: /s/ Guy Miller

Guy Miller, Authorized Signatory

 

CITADEL GP LLC

 

By: /s/ Noah Goldberg

Noah Goldberg, Authorized Signatory

 

KENNETH GRIFFIN

 

By: /s/ Noah Goldberg

Noah Goldberg, attorney-in-fact*

 

 

*Noah Goldberg is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney filed with the Securities and Exchange Commission herewith as Exhibit 24.

 

 

 


 

 

 

EXHIBIT 24

 

POWER OF ATTORNEY

 

The undersigned hereby constitutes and appoints Noah Goldberg as the undersigned's true and lawful authorized representative and attorney-in-fact to execute for and on behalf of the undersigned and to file with the United States Securities and Exchange Commission and any other authority: (1) any Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the “1934 Act”), and the rules promulgated thereunder; and (2) any Schedule 13D or Schedule 13G, and any amendments thereto, on behalf of the undersigned in accordance with Section 13 of the 1934 Act and the rules promulgated thereunder.

 

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, hereby ratifying and confirming all that such attorney-in-fact shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney- in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Section 16 or Section 13 or any other provision of the 1934 Act.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any Forms 3, 4 and 5 or Schedule 13D or 13G, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of March 19, 2020.

 

 

 

/s/ KENNETH GRIFFIN

Kenneth Griffin

 

 

 

 

 

EXHIBIT 99.1

 

JOINT FILING AGREEMENT

 

The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Zentalis Pharmaceuticals, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned.

 

This Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.

 

Dated this 9th day of April, 2020.

 

CITADEL SECURITIES LLC

 

By: /s/ Guy Miller

Guy Miller, Authorized Signatory

 

CITADEL ADVISORS LLC

 

By: /s/ Noah Goldberg

Noah Goldberg, Authorized Signatory

 

CALC IV LP

 

By: /s/ Guy Miller

Guy Miller, Authorized Signatory

 

CITADEL ADVISORS HOLDINGS LP

 

By: /s/ Noah Goldberg

Noah Goldberg, Authorized Signatory

 

CITADEL SECURITIES GP LLC

 

By: /s/ Guy Miller

Guy Miller, Authorized Signatory

 

CITADEL GP LLC

 

By: /s/ Noah Goldberg

Noah Goldberg, Authorized Signatory

 

KENNETH GRIFFIN

 

By: /s/ Noah Goldberg

Noah Goldberg, attorney-in-fact*

 

 

*Noah Goldberg is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney filed with the Securities and Exchange Commission herewith as Exhibit 24.